Christophe Bontoux, Marie Csanyi-Bastien, Corinne Bouvier, Frédérique Larousserie, Hervé Sartelet, Marie-Paule Algros, Frédéric Bibeau, Sébastien Aubert, Gonzague de Pinieux, Marie Faruch-Bilfeld, Natacha Roussel, Sofia Galanou, Nathalie Van Acker, David Grand, Mélanie Larquier, Sophie Peries, Pierre Brousset, Solène Evrard, Anne Gomez-Mascard
{"title":"FOS gene fusions in osteosarcoma raise the hypothesis of malignant transformation of osteoblastoma.","authors":"Christophe Bontoux, Marie Csanyi-Bastien, Corinne Bouvier, Frédérique Larousserie, Hervé Sartelet, Marie-Paule Algros, Frédéric Bibeau, Sébastien Aubert, Gonzague de Pinieux, Marie Faruch-Bilfeld, Natacha Roussel, Sofia Galanou, Nathalie Van Acker, David Grand, Mélanie Larquier, Sophie Peries, Pierre Brousset, Solène Evrard, Anne Gomez-Mascard","doi":"10.1007/s00428-025-04202-6","DOIUrl":null,"url":null,"abstract":"<p><p>Osteosarcoma is the most common malignant bone tumor among children and young adults. Distinguishing between osteoblastoma and osteosarcoma can be particularly challenging, especially in small tissue samples and for the osteoblastoma-like osteosarcoma subtype. Recent studies with conflicting results have suggested a potential malignant transformation process from osteoblastoma to osteosarcoma. This study aims to investigate the hypothesis of osteoblastoma evolving into osteosarcoma and to discuss its clinical implications. We conducted a retrospective multicentric case-series study, collecting clinical, radiological, histological, and follow-up data from osteosarcoma cases suspected to have originated from malignant transformation of osteoblastoma within the French ResOs network. Molecular analyses (fluorescence in situ hybridization (FISH) and next-generation sequencing (NGS)) were performed. We included two cases (one female and one male), with a median age at osteosarcoma diagnosis of 42 and 73 years old, respectively. One patient had tumor located in the axial skeleton, and both cases exhibited features of osteoblastoma-like osteosarcoma. Notably, one of the patients had a documented history of osteoblastoma diagnosed sixteen years earlier. FISH analysis revealed FOS rearrangements in both osteosarcoma cases, with tumors presenting uncommon fusion transcripts (FOS::VGLL4 and FOS::COL5A2) identified through NGS. Both patients were alive at last follow-up. Our findings suggest that osteosarcoma can rarely present with FOS gene fusions and be associated with an indolent progression, challenging the specificity of such signatures for osteoblastoma diagnosis. This discovery also raises the hypothesis of malignant transformation from osteoblastoma to osteosarcoma and underscores the necessity for diligent monitoring of FOS-rearranged bone-forming tumors for optimal therapeutic management.</p>","PeriodicalId":23514,"journal":{"name":"Virchows Archiv","volume":" ","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Virchows Archiv","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00428-025-04202-6","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PATHOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Osteosarcoma is the most common malignant bone tumor among children and young adults. Distinguishing between osteoblastoma and osteosarcoma can be particularly challenging, especially in small tissue samples and for the osteoblastoma-like osteosarcoma subtype. Recent studies with conflicting results have suggested a potential malignant transformation process from osteoblastoma to osteosarcoma. This study aims to investigate the hypothesis of osteoblastoma evolving into osteosarcoma and to discuss its clinical implications. We conducted a retrospective multicentric case-series study, collecting clinical, radiological, histological, and follow-up data from osteosarcoma cases suspected to have originated from malignant transformation of osteoblastoma within the French ResOs network. Molecular analyses (fluorescence in situ hybridization (FISH) and next-generation sequencing (NGS)) were performed. We included two cases (one female and one male), with a median age at osteosarcoma diagnosis of 42 and 73 years old, respectively. One patient had tumor located in the axial skeleton, and both cases exhibited features of osteoblastoma-like osteosarcoma. Notably, one of the patients had a documented history of osteoblastoma diagnosed sixteen years earlier. FISH analysis revealed FOS rearrangements in both osteosarcoma cases, with tumors presenting uncommon fusion transcripts (FOS::VGLL4 and FOS::COL5A2) identified through NGS. Both patients were alive at last follow-up. Our findings suggest that osteosarcoma can rarely present with FOS gene fusions and be associated with an indolent progression, challenging the specificity of such signatures for osteoblastoma diagnosis. This discovery also raises the hypothesis of malignant transformation from osteoblastoma to osteosarcoma and underscores the necessity for diligent monitoring of FOS-rearranged bone-forming tumors for optimal therapeutic management.
期刊介绍:
Manuscripts of original studies reinforcing the evidence base of modern diagnostic pathology, using immunocytochemical, molecular and ultrastructural techniques, will be welcomed. In addition, papers on critical evaluation of diagnostic criteria but also broadsheets and guidelines with a solid evidence base will be considered. Consideration will also be given to reports of work in other fields relevant to the understanding of human pathology as well as manuscripts on the application of new methods and techniques in pathology. Submission of purely experimental articles is discouraged but manuscripts on experimental work applicable to diagnostic pathology are welcomed. Biomarker studies are welcomed but need to abide by strict rules (e.g. REMARK) of adequate sample size and relevant marker choice. Single marker studies on limited patient series without validated application will as a rule not be considered. Case reports will only be considered when they provide substantial new information with an impact on understanding disease or diagnostic practice.